Notice of final decision to amend (or not amend) the current Poisons Standard - ACMS #41, ACCS #36, Joint ACMS-ACCS #33

This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS and 42ZCZX, this notice publishes the:

• A decision made by a delegate of the Secretary pursuant to regulations 42ZCZR and 42ZCZU;
• reasons for that final decision; and
• date of effect of the decision.

Final decision and reasons

We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au.

Contents

• 1 Notice of final decisions to amend (or not amend) the current Poisons Standard
• 2 Final decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #41, March 2023)
  • 2.1 Final decision in relation to celecoxib
• 3 Final decisions on proposed amendments referred to the Advisory Committee on Medicines and Chemicals Scheduling (ACMS-ACCS #33, March 2023)
  • 3.1 Final decision in relation to azelaic acid
• 4 Final decisions on proposed amendments referred to the Advisory Committee on Chemicals Scheduling (ACCS #36, March 2023)
  • 4.1 Final decision in relation to bromoxynil
  • 4.2 Final decision in relation to dioxane
• 5 Amendments to the Poisons Standard made as delegate-only decisions
  • 5.1 Final decision in relation to salbutamol
  • 5.2 Final decision in relation to nitazenes
  • 5.3 Final decision in relation to velagliflozin
  • 5.4 Final decision in relation to vadadustat
• 6 Amendments to the Poison Standard in relation to New Chemical Entities (NCEs)
  • 6.1 Concizumab
  • 6.2 Givosiran
  • 6.3 Glofitamab
  • 6.4 Imlifidase
  • 6.5 Mirikizumab
  • 6.6 Olipudase alfa
  • 6.7 Rimegepant
  • 6.8 Selpercatinib
  • 6.9 Spesolimab
  • 6.10 Tafasitamab
  • 6.11 Tagraxofusp
  • 6.12 Teclistamab
  • 6.13 Tirbanibulin